AR055145A1 - Derivados de pirazolona - Google Patents
Derivados de pirazolonaInfo
- Publication number
- AR055145A1 AR055145A1 ARP060103758A ARP060103758A AR055145A1 AR 055145 A1 AR055145 A1 AR 055145A1 AR P060103758 A ARP060103758 A AR P060103758A AR P060103758 A ARP060103758 A AR P060103758A AR 055145 A1 AR055145 A1 AR 055145A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- bicyclo
- tetrahydro
- methyl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 5
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- QEYQSYAGLRIYBE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,2-benzodiazepine Chemical compound C1CCNNC2=CC=CC=C21 QEYQSYAGLRIYBE-UHFFFAOYSA-N 0.000 abstract 2
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 abstract 2
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 abstract 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 abstract 2
- UCVQOTUUPQTMJU-UHFFFAOYSA-N 1,2,3,4,6,7,8,9-octahydroindazolo[1,2-a]indazole-10,12-dione Chemical compound C1CCCC2=C1N1C(CCCC3)=C3C(=O)N1C2=O UCVQOTUUPQTMJU-UHFFFAOYSA-N 0.000 abstract 1
- LDHZGHNEBZYUSL-UHFFFAOYSA-N 1-ethyl-2-phenyl-5,6-dihydro-4h-cyclopenta[c]pyrazol-3-one Chemical compound CCN1C=2CCCC=2C(=O)N1C1=CC=CC=C1 LDHZGHNEBZYUSL-UHFFFAOYSA-N 0.000 abstract 1
- DRMOBFBTSAFUGB-UHFFFAOYSA-N 1-methyl-2-phenyl-4,5,6,7-tetrahydroindazol-3-one Chemical compound CN1C=2CCCCC=2C(=O)N1C1=CC=CC=C1 DRMOBFBTSAFUGB-UHFFFAOYSA-N 0.000 abstract 1
- RRCZYNLFYLGBIV-UHFFFAOYSA-N 1-methyl-2-phenyl-5,6-dihydro-4h-cyclopenta[c]pyrazol-3-one Chemical compound CN1C=2CCCC=2C(=O)N1C1=CC=CC=C1 RRCZYNLFYLGBIV-UHFFFAOYSA-N 0.000 abstract 1
- QMLAPQOJLFKESK-UHFFFAOYSA-N 5-cyclopropyl-1-methyl-2-phenyl-4-propan-2-ylpyrazol-3-one Chemical compound CN1N(C=2C=CC=CC=2)C(=O)C(C(C)C)=C1C1CC1 QMLAPQOJLFKESK-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- -1 arylcyclopropyl Chemical group 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005347 halocycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Pueden utilizarse en forma de composiciones farmacéuticas, para su uso en trastornos metabolicos. Reivindicacion 1: Compuestos de la formula (1) en la que R1 es hidrogeno, alquilo, cicloalquilo, cicloalquilalquilo, aralquilo, haloalquilo, arilo, piridinilmetilo o heterociclilo; y con la condicion de que, en el caso de que R1 sea hidrogeno, entonces R3 sea adamantanilo o adamantilo, sustituido de una a tres veces por sustituyentes elegidos con independencia entre sí entre alquilo, hidroxi, halogeno y haloalquilo; R2 es hidrogeno, alquilo, cicloalquilo, arilo, aralquilo, benzotiazolilo, biciclo(2.2.1)heptilo o biciclo(2.2.2)octilo, en los que biciclo(2.2.1)heptilo y biciclo(2.2.2)octilo están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos con independencia entre sí entre alquilo, hidroxi, halogeno y haloalquilo; o R1 y R2 junto con los átomos de nitrogeno a los que están unidos forman pirazolidina, hexahidro-piridazina, (1,2)-diazepano o 2,3,4,5- tetrahidro-1H-benzo(c)(1,2)diazepina, en los que la pirazolidina, hexahidro-piridazina, (1,2)diazepano y 2,3,4,5- tetrahidro-1H-benzo(c)(1,2)diazepina están opcionalmente sustituidos de una a tres veces por grupos alquilo; o R1 y R4, juntos, forman - (CH2) m-; m es el numero 3, 4, 5 o 6; R3 es ciclopropilo, arilciclopropilo, isopropilo, tert-butilo, adamantanilo o biciclo(2.2.2)octilo, en los que adamantanilo y biciclo(2.2.2)octilo están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos con independencia entre sí entre alquilo, hidroxi, halogeno y haloalquilo; R4 es hidrogeno, alquilo, cicloalquilo, ariloxialquilo, alquilcarbonilaminoariloxialquilo, alquiloxialquilo, arilo, aralquilo, haloalquilo o halocicloalquilo; o R3 y R4, juntos, forman -(CH2)n-; n es el numero3, 4,5 o 6; y sales y ésteres farmacéuticamente aceptables de los mismos; con la condicion de que, en el caso de que R3 y R4, juntos, formen -(CH2)n-, entonces R1 sea alquilo y no sea hidrogeno o alquilo; y con la condicion de que, en el caso de que R4 sea hidrogeno o alquilo, entonces R3 no sea isopropilo; y con la condicion de que se excluyan la 3-ciclopropil-4-isopropil-2-metil-1-fenil-3-pirazolin-5-ona; 1,2-dihidro-5- metil-4-triciclo(3.3.1.13,7)dec-1- il-3H-pirazol-3-ona; 1,2,3,4,6,7,8,9-octahidro-10H,12H-indazolo(1,2-a)indazol-10,12-diona; 1,2,4,5,6,7-hexahidro-1-metil-2-fenil-3H-indazol-3- ona; 1,4,5,6-tetrahidro-1-metil-2-fenil-3(2H)-ciclopentapirazolona; 1,4,5,6-tetrahidro-1-bencil-2-fenil-3(2H)-ciclopentapirazolona; 1,4,5,6- tetrahidro-1-etil-2-(4-metil)-fenil-3(2H)-ciclopentapirazolona; 1,4,5,6-tetrahidro-1-etil-2-fenil-3(2H)-ciclopentapirazolona; y 1,4,5,6,7,8- hexahidro-1-metil-2-fenil-3(2H)- cicloheptapirazolona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107970 | 2005-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055145A1 true AR055145A1 (es) | 2007-08-08 |
Family
ID=37729936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103758A AR055145A1 (es) | 2005-08-31 | 2006-08-29 | Derivados de pirazolona |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7652057B2 (es) |
| EP (1) | EP1924562A2 (es) |
| JP (1) | JP5073664B2 (es) |
| KR (1) | KR100982088B1 (es) |
| CN (1) | CN101243050B (es) |
| AR (1) | AR055145A1 (es) |
| AU (1) | AU2006286646B2 (es) |
| BR (1) | BRPI0615039A2 (es) |
| CA (1) | CA2618840C (es) |
| CR (1) | CR9703A (es) |
| EC (1) | ECSP088229A (es) |
| IL (1) | IL189186A0 (es) |
| MA (1) | MA29775B1 (es) |
| MX (1) | MX2008002583A (es) |
| MY (1) | MY145464A (es) |
| NO (1) | NO20080554L (es) |
| NZ (1) | NZ565536A (es) |
| RU (1) | RU2407737C2 (es) |
| TW (1) | TWI332949B (es) |
| UA (1) | UA90742C2 (es) |
| WO (1) | WO2007025880A2 (es) |
| ZA (1) | ZA200801444B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428467B2 (en) | 2008-11-20 | 2016-08-30 | Northwestern University | Selective calcium channel antagonists |
| US9145424B2 (en) | 2008-11-20 | 2015-09-29 | Northwestern University | Treatment of amyotrophic lateral sclerosis |
| US10167263B2 (en) * | 2008-11-20 | 2019-01-01 | Northwestern University | Treatment of amyotrophic lateral sclerosis |
| JP5791595B2 (ja) | 2009-05-22 | 2015-10-07 | アッヴィ・インコーポレイテッド | ５−ｈｔ受容体の調節剤およびそれの使用方法 |
| WO2011051958A1 (en) | 2009-10-30 | 2011-05-05 | E.I. Du Pont De Nemours And Company | Fungicidal pyrazolones |
| KR101770979B1 (ko) * | 2010-05-21 | 2017-08-24 | 애브비 인코포레이티드 | 5ｈｔ 수용체의 조절제 및 이의 사용방법 |
| EP2881387A1 (en) | 2013-12-09 | 2015-06-10 | Basf Se | Pyrazolone compounds having herbicidal activity |
| EP2881388A1 (en) | 2013-12-09 | 2015-06-10 | Basf Se | Pyrazolone compounds having herbicidal activity |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| WO2019048988A1 (en) | 2017-09-08 | 2019-03-14 | Pi Industries Ltd. | Novel fungidal heterocyclic compounds |
| JP2020533303A (ja) | 2017-09-08 | 2020-11-19 | ピーアイ インダストリーズ リミテッドＰｉ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ | 新規な殺菌性複素環化合物 |
| WO2020210922A1 (es) * | 2019-04-17 | 2020-10-22 | Pontificia Universidad Católica De Chile | Derivados de adamantiloxadiazoles y sus solvatos, hidratos y sales farmacéuticamente aceptables del mismo, composición farmacéutica que los comprende, proceso de síntesis, útiles como inhibidores efectivos y selectivos de la actividad reductasa de la enzima 11-beta deshidrogenasa tipo 1 (11β-hsd1) |
| CN113527207B (zh) * | 2020-04-22 | 2023-06-06 | 常州强力电子新材料股份有限公司 | 乙氧基/丙氧基改性的吡唑啉有机物、其应用、光固化组合物及光刻胶 |
| CN112375072B (zh) * | 2020-09-28 | 2021-05-28 | 上海长征富民金山制药有限公司 | 吡唑啉酮衍生物、注射剂及其用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2731473A (en) * | 1956-01-17 | New pyrazolone derivatives | ||
| DE668628C (de) | 1935-12-08 | 1938-12-07 | Beiersdorf & Co A G P | Verfahren zur Darstellung von Alkyl- und Aralkylabkoemmlingen der 3,4-Cyclotetramethylen-1-aryl-5-pyrazolone |
| JPS609752B2 (ja) * | 1979-11-09 | 1985-03-12 | 東邦新薬株式会社 | 新規な２−アセトキシベンズアミド誘導体、その製法及びそれを有効成分とする医薬 |
| DE4415484A1 (de) | 1994-05-03 | 1995-11-09 | Basf Ag | Verfahren zur Herstellung von 1-(Het)aryl-3-hydroxy-pyrazolen |
| US5663365A (en) * | 1996-10-29 | 1997-09-02 | Japan Hydrazine Co., Ltd. | Process for the preparation of pyrazolones |
| ATE219044T1 (de) * | 1997-04-10 | 2002-06-15 | Pfizer | Fluorosubstituierte adamantan-derivate |
| TW536387B (en) * | 1998-04-23 | 2003-06-11 | Sumitomo Chemical Co | Pyrazolinone compound |
| DK1213296T3 (da) * | 1999-08-31 | 2004-08-16 | Kissei Pharmaceutical | Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf |
| WO2002053573A1 (en) * | 2000-12-28 | 2002-07-11 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| DE60332743D1 (de) * | 2002-08-08 | 2010-07-08 | Kissei Pharmaceutical | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung |
| AU2003262023A1 (en) * | 2002-09-10 | 2004-04-30 | Takeda Pharmaceutical Company Limited | Five-membered heterocyclic compounds |
| ES2364046T3 (es) | 2002-12-19 | 2011-08-23 | Bristol-Myers Squibb Company | Gamma-carbolinas tricíclicas sustituidas utilizadas como agonistas y antagonistas de los receptores de la serotonina. |
| GB0306718D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| AU2004265299B2 (en) * | 2003-08-07 | 2008-05-01 | Merck & Co., Inc. | Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| GB2637773A (en) * | 2024-02-05 | 2025-08-06 | Nokia Technologies Oy | Access traffic steering, switching, splitting (ATSSS) between access paths |
-
2006
- 2006-08-21 AU AU2006286646A patent/AU2006286646B2/en not_active Ceased
- 2006-08-21 RU RU2008111971/04A patent/RU2407737C2/ru not_active IP Right Cessation
- 2006-08-21 CN CN2006800305234A patent/CN101243050B/zh not_active Expired - Fee Related
- 2006-08-21 JP JP2008528461A patent/JP5073664B2/ja not_active Expired - Fee Related
- 2006-08-21 UA UAA200803780A patent/UA90742C2/ru unknown
- 2006-08-21 WO PCT/EP2006/065471 patent/WO2007025880A2/en not_active Ceased
- 2006-08-21 NZ NZ565536A patent/NZ565536A/en not_active IP Right Cessation
- 2006-08-21 CA CA2618840A patent/CA2618840C/en not_active Expired - Fee Related
- 2006-08-21 BR BRPI0615039-0A patent/BRPI0615039A2/pt not_active IP Right Cessation
- 2006-08-21 KR KR1020087004807A patent/KR100982088B1/ko not_active Expired - Fee Related
- 2006-08-21 EP EP06792909A patent/EP1924562A2/en not_active Withdrawn
- 2006-08-21 MX MX2008002583A patent/MX2008002583A/es active IP Right Grant
- 2006-08-21 MY MYPI20080416A patent/MY145464A/en unknown
- 2006-08-29 US US11/511,542 patent/US7652057B2/en not_active Expired - Fee Related
- 2006-08-29 AR ARP060103758A patent/AR055145A1/es unknown
- 2006-08-29 TW TW095131856A patent/TWI332949B/zh not_active IP Right Cessation
-
2008
- 2008-01-29 CR CR9703A patent/CR9703A/es not_active Application Discontinuation
- 2008-01-30 NO NO20080554A patent/NO20080554L/no not_active Application Discontinuation
- 2008-02-03 IL IL189186A patent/IL189186A0/en unknown
- 2008-02-12 ZA ZA200801444A patent/ZA200801444B/xx unknown
- 2008-02-27 EC EC2008008229A patent/ECSP088229A/es unknown
- 2008-03-14 MA MA30744A patent/MA29775B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101243050A (zh) | 2008-08-13 |
| US20070049574A1 (en) | 2007-03-01 |
| JP5073664B2 (ja) | 2012-11-14 |
| KR100982088B1 (ko) | 2010-09-13 |
| MY145464A (en) | 2012-02-15 |
| UA90742C2 (en) | 2010-05-25 |
| US7652057B2 (en) | 2010-01-26 |
| CN101243050B (zh) | 2012-07-04 |
| CR9703A (es) | 2008-02-20 |
| ZA200801444B (en) | 2008-12-31 |
| BRPI0615039A2 (pt) | 2011-04-26 |
| HK1123295A1 (en) | 2009-06-12 |
| TWI332949B (en) | 2010-11-11 |
| AU2006286646B2 (en) | 2010-09-23 |
| WO2007025880A3 (en) | 2007-05-03 |
| ECSP088229A (es) | 2008-03-26 |
| JP2009506089A (ja) | 2009-02-12 |
| KR20080031482A (ko) | 2008-04-08 |
| RU2008111971A (ru) | 2009-10-10 |
| IL189186A0 (en) | 2008-06-05 |
| AU2006286646A1 (en) | 2007-03-08 |
| CA2618840C (en) | 2011-07-05 |
| NZ565536A (en) | 2011-03-31 |
| RU2407737C2 (ru) | 2010-12-27 |
| MX2008002583A (es) | 2008-03-18 |
| TW200740764A (en) | 2007-11-01 |
| CA2618840A1 (en) | 2007-03-08 |
| MA29775B1 (fr) | 2008-09-01 |
| NO20080554L (no) | 2008-03-14 |
| WO2007025880A2 (en) | 2007-03-08 |
| EP1924562A2 (en) | 2008-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055145A1 (es) | Derivados de pirazolona | |
| CY1118292T1 (el) | Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων | |
| UY33921A (es) | Oxazinopteridinas y oxazinoptiridinonas n-sustituidas | |
| ECSP10010178A (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| UY31193A1 (es) | Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]-piridazina, su preparasción y su aplicación en terapéutica | |
| UY31468A1 (es) | Derivados bis-(sulfonilamino) en terapia 065 | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| NI201000109A (es) | Derivados bis-(sulfonilamino) para uso en terapia. | |
| ECSP099750A (es) | Imidazoquinolinas con propiedades inmunomoduladoras | |
| PA8795301A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| CR9587A (es) | Derivados de piridazina | |
| MX2010007023A (es) | Agonistas del receptor glucocorticoide sustituido de c20-c21. | |
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| ECSP088774A (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricación. | |
| ECSP088971A (es) | Ligandos 101 de los receptores nicotínicos de acetilcolina | |
| AR061980A1 (es) | Acilanilidas sustituidas y metodos para su utilizacion | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR063118A1 (es) | Derivados de sulfonamida-piperidina composiciones farmaceuticas que los contienen y usos en enfermedades y trastornos inflamatorios alergicos y respiratorios | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| PA8783601A1 (es) | Derivados de piperidina/piperazina | |
| UY27646A1 (es) | Derivados de quinolina como antagonistas de npt | |
| AR073077A1 (es) | Uso de dabigatran. compuesto. composicion farmaceutica- | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UY31457A1 (es) | Derivados acidos de cicloalquilamino | |
| ECSP109900A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |